Is Travere Therapeutics Inc (TVTX) overvalued? · rev $233.2M
Travere Therapeutics Inc (TVTX) is a biotechnology company listed on US.
This page asks whether Travere Therapeutics Inc (TVTX) looks expensive on cached numbers — not a short thesis.
Latest reported TVTX revenue for 2024-12-31 was $233.2M. Net income was -$321.5M. Revenue was up 417.5% from 2023-12-31 to 2024-12-31. TVTX currently screens at market cap $1.33B.
TVTX currently screens at market cap $1.33B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TVTX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TVTX stock page for the full model, not this heading.
Not investment advice.